A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma (Q33405134)

26 July 2017

title

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma (English)

1 reference

26 July 2017

1 reference

Paolo Corradini

3

0 references

Athanasios Dimopoulos

object named as

Meletios A Dimopoulos

5

0 references

author name string

Maria T Petrucci

1

1 reference

26 July 2017

Pilar Giraldo

2

1 reference

26 July 2017

Adriana Teixeira

4

1 reference

26 July 2017

Igor W Blau

6

1 reference

26 July 2017

Johannes Drach

7

1 reference

26 July 2017

Ralf Angermund

8

1 reference

26 July 2017

Nathalie Allietta

9

1 reference

26 July 2017

Esther Broer

10

1 reference

26 July 2017

Vivien Mitchell

11

1 reference

26 July 2017

Joan Bladé

12

1 reference

26 July 2017

language of work or name

English

0 references

publication date

7 January 2013

1 reference

British Journal of Haematology

26 July 2017

published in

1 reference

26 July 2017

volume

160

1 reference

26 July 2017

issue

5

1 reference

26 July 2017

page(s)

649-659

1 reference

A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma

26 July 2017

cites work

1 reference

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

21 January 2018

1 reference

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

21 January 2018

1 reference

A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma

21 January 2018

1 reference

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy.

21 January 2018

1 reference

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

21 January 2018

1 reference

Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.

21 January 2018

1 reference

An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma

21 January 2018

1 reference

Emerging therapies for the treatment of relapsed or refractory multiple myeloma

21 January 2018

1 reference

Estimates of cancer incidence and mortality in Europe in 2008.

21 January 2018

1 reference

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

21 January 2018

1 reference

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

21 January 2018

1 reference

Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland

21 January 2018

1 reference

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).

21 January 2018

1 reference

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

21 January 2018

1 reference

Clinical course of patients with relapsed multiple myeloma

21 January 2018

1 reference

Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety

21 January 2018

1 reference

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

21 January 2018

1 reference

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

21 January 2018

1 reference

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program

21 January 2018

1 reference

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

21 January 2018

1 reference

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

21 January 2018

1 reference

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

21 January 2018

Cancer statistics, 2012

1 reference

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

21 January 2018

1 reference

Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib

21 January 2018

1 reference

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

21 January 2018

1 reference

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.12198

1 reference

26 July 2017

1 reference